Chugai Pharmaceutical Co., Ltd.
Research Chugai Pharmaceutical Co., Ltd. (4519) on Bullrun: market cap JPY 10.70T, P/E 22.7, dividend yield 3.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4519
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyJPY
- Market capJPY 10.70T
- P/E22.7
- Dividend yield3.5%
- Financial periodFY2025
- RevenueJPY 1.26T
- Revenue growth7.5%
- Free cash flowJPY 274.67B
- Gross margin71.1%
Valuation Snapshot
latest market cap is JPY 10.70T; P/E is 22.7; dividend yield is 3.5%.
Peer valuation comparison
Latest P/E is 22.67x versus a Healthcare sector median of 24.61x (7.9% below).
Latest dividend yield is 3.52% versus a Healthcare sector median of 1.84% (91.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 1.26T | n/a | JPY 274.67B | 71.1% | 263.72 | JPY 426.60B | n/a | JPY 2.03T |
| FY2024 | JPY 1.17T | n/a | JPY 392.70B | 71.0% | 235.36 | JPY 540.20B | n/a | JPY 1.90T |
| FY2023 | JPY 1.11T | n/a | JPY 335.67B | 62.8% | 197.8 | JPY 458.67B | n/a | JPY 1.63T |
| FY2022 | JPY 1.26T | n/a | JPY 172.34B | 62.2% | 227.57 | JPY 222.17B | n/a | JPY 1.42T |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-15 | JPY 10.70T | 22.7 | 2.0% | 132 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 132 JPY, yield 3.5%.
| Year | Dividends/share |
|---|---|
| FY2025 | 272 JPY |
| FY2024 | 98 JPY |
| FY2023 | 80 JPY |
| FY2022 | 78 JPY |
| FY2021 | 76 JPY |
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant;
ETFs that hold Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. is one of the ten largest holdings of 3 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| UBS MSCI Japan Climate Paris Aligned UCITS ETF JPY acc | 4.31% | 0.12% |
| HSBC MSCI Japan Climate Paris Aligned UCITS ETF | 4.33% | 0.18% |
| UBS MSCI Japan Climate Paris Aligned UCITS ETF ir-hEUR acc | 4.31% | 0.15% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Chugai Pharmaceutical Co., Ltd.'s market cap?
Chugai Pharmaceutical Co., Ltd.'s market capitalization is JPY 10.70T.
What is Chugai Pharmaceutical Co., Ltd.'s P/E ratio?
Chugai Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 22.7.
Does Chugai Pharmaceutical Co., Ltd. pay a dividend?
Chugai Pharmaceutical Co., Ltd. has a dividend yield of 3.5%.
What does Chugai Pharmaceutical Co., Ltd. do?
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.